贵阳中医治疗下肢深静脉血栓(贵阳红胎记科哪个医院好) (今日更新中)

At the Good Times Burgers & Frozen Custard in Denver, Colorado, this robot, Holly, is working the morning rush. Holly is cutting the drive through time by 10 to 15 seconds.For 20 years, worker Orlina has been taking orders and serving up food. She says Holly is one of the most helpful employees on staff. “It’s really fast and helps us with the speed a lot,” she says.The creator behind this artificial intelligence technology is Valyant. Rob Carpenter, the CEO of the company, says as jobs evolve and change, new jobs become available. As with most new technology, Carpenter says they’re still working out all the kinks. “It’s almost understanding the almost infinite ways to that people can ask for a cheeseburger,” Carpenter explains. “There are also the different accents you have to content with and the background noises.” While customers find the idea of Holly fun, their still unsure. “It was awkward,” says one customer. “And humans are just better and more responsive and talkative.” Carpenter admits Holly isn't the perfect employee, but he says in the next five years, you will see more robots at big name stores and fast-food restaurants."Right now, this is ground zero handling drive through,” he says. “Eventually, we are going to start seeing it in more tangible ways, where it can actually carry on a more fluid conversation." Carpenter says the opportunities are limitless. 1410

CHICAGO, Ill. – Shortages of ventilators and personal protective equipment mean many healthcare providers are going into battle unarmed. It’s sparked a heated debate behind closed doors about balancing efforts to save patients versus exposing doctors and nurses to the virus. Who lives? Who dies? Who gets priority to a ventilator? All complex questions health providers are being confronted with. “We've never had this situation before. This is unprecedented,” said Craig Klugman a professor of bioethics at DePaul University in Chicago. Bioethicists say widespread infection, protective equipment and ventilator shortages are creating unique ethical dilemmas for healthcare workers. “We will start to care for the person who is at risk of dying first,” explained Dr. Ricardo Gonzalez-Fisher, a surgical oncologist who teaches healthcare ethics at Metropolitan State University of Denver. “But if we have more people than resources that we have to. Try to save those that are savable.” “The obligation for a healthcare provider to treat the patient doesn't necessarily have a limit,” said Klugman. In Spain, some 13,000 medical workers have been infected. In Italy, more than 60 workers have died since the outbreak began. “It's not just their life. They can assume this risk for themselves,” said Klugman. “If they don’t have the right equipment, they also have the risk of infecting other patients, other healthcare providers. Their family.” Some health systems around the country are reportedly discussing unilateral do-not-resuscitate policies. It’s something that was debated during the Ebola outbreak in 2015. Determining who gets treatment and who does not is something Klugman says is taken very seriously. “We think about it very carefully and with great deliberation.” In Italy, that meant denying some care to the elderly in favor of the young. Klugman says in Illinois, a pandemic flu plan created a decade ago includes care procedures built around ethical frameworks and algorithms that help decide who should for example, get a ventilator. “We have to consider things like what is our most important value. So, the value that we're considering is maximizing the number of years of life that we can save,” said Klugman. Ultimately, a balance must be struck. “You have to make sure that the benefit of the patient overrides the harm or the risk that you're getting in,” said Dr. Gonzalez-Fisher. Otherwise, bioethicists say there may not be enough first responders to treat the infected.“When you call 9-1-1 because your loved one can't breathe, there will be nobody coming. That's the worst-case scenario,” said Klugman. 2653

On Thursday, the United States Air Force Academy announced that President Trump nominated Lt. General Richard M. Clark to become the Academy's first Black superintendent. According to the U.S. Air Force Academy, if the Senate confirms Lt. Gen. Clark's nomination, he will become the second Black general to head up a service academy. He will be in charge of the Academy's undergraduate academic program, cadet military, and athletic training and character development.“I am extremely humbled and honored by the nomination to serve as the Superintendent of the Air Force Academy,” said Lt. Gen. Clark. “I’m also excited for the opportunity to build on the tremendous work of Lt. Gen. [Jay] Silveria and to give back to the institution that has given me so much. Go Falcons!”Clark has a history of leadership with the Air Force Academy, previously working as the Commandment of Cadets and at other levels of Air Force Command. He has pilot expertise as well, ranging from bomber to air-refueling. He currently leads the nuclear expertise for the Air Force at the Pentagon.“I have no doubt that Lt. Gen. Clark will be an extraordinary leader for the Academy,” Silveria said. “He has a long history with USAFA and an exceptional leadership record.”Clark will replace Silveria after 35 years of committed service to the nation and the Air Force. He has commanded the Academy for the last three years.Silvera is expected to retire later this year. This article was written by Samantha Alexander for KOAA. 1522

FONTANA, Calif. -- Metal scrappers aren’t making as much money as what they used to. “A long time ago we got maybe 14 or 15 bucks,” Harry Sawyer said. “But now we get maybe .” Sawyer has been scrapping metal for more than a decade and says he’s never seen prices this low. “I don’t feel good about it,” he said. “I don’t feel good about it.” Workers at American Metal Recycling in Southern California say the prices started dropping soon after international tariffs hit. “We are talking anywhere between 0 to what it is now a ton,” said metal buyer Erick Valdez. “So, it’s half price. It’s pretty bad.” Valdez says all metals – including steel, aluminum and copper – were all hit hard. “There’s really nothing that made it through pretty good through these tariff wars,” he said. Everything was messed with.” With less money to make, Valdez is seeing less people recycling metal. “Before we’d recognize what their name was – first and last name,” he said. “Now we’re like, ‘what’s your name again?’” So why should you care if metal scrappers are making less money? Well, international economists say when prices are raised by tariffs – that increase in cost is passed to consumers – and ultimately hurts other parts of the economy. “There have been some analysts that say for every steel job you save, you loss 16 in the rest of the economy,” said Walter Hutchins, J.D. M.A., a professor of global business at the University of Redlands. “If the regular Joe is union worker for US Steel, he may or she may have gotten some kind temporary benefit from the tariffs,” he said. “But when that same worker goes to buy a F-150 pickup or his pension fund has shares of Ford Motor Company stock in it, that average Joe could be quite harmed.” While the sticker shock might be driving some scrappers away, other metal industries say they are flourishing. “You can be a high school dropout and you can still make 0,000 in my industry,” said Randy McClure, who owns and operates the Welding Skills Test and Training Center in Rancho Cucamonga. Though he’s seeing the price change in metals, McClure is also seeing the demand change for work. “I don’t know if it’s more work because the tariffs came in but there is more work than there are people to do the work,” he said. “Not having enough workers is a bigger problem than the tariffs. That’s for sure.” But for the scrappers out there on the streets and the workers recycling the metal, the small payoff could impact this industry’s future big time. 2530

DENVER, Colo. -- Megan Fischer’s life story is one of strength and triumph. Her black belt in taekwondo is proof of her ability to persevere when mind and body are pushed to their limits. It’s a challenge she chooses to take part in. However, there was a time about 15 years ago when she had to overcome a challenge that wasn't planned. “In June of 2001, I was diagnosed with a brain tumor. It was explained to me as being roughly the size of an average-sized human fist. So relatively large in the head of a 6-year-old,” Megan Fischer said. Fischer is a childhood cancer survivor. “I remember just kind of a lot of times feeling like ‘why I am I here, why am I in this situation where I’m being hurt.'” After a surgery to remove the tumor, Fischer underwent chemotherapy for 11 months. It made her very sick. But it worked, and a couple years later, Fischer was cancer free. “Now I just kind of try and advocate for other kids with cancer, and kind of help them through.” Fischer is hoping to raise awareness of the shortage of the chemo drug Vincristine. It was part of her treatment many years ago. “I don’t know if it was the reason why I was able to have so much success in my tumor disappearing, but I definitely know that the side effects of Vincristine are pretty terrible. So I don’t think that my doctors would have put me on it if they didn’t think it was going to play a role in my chemotherapy treatments,” Fischer said. Dr. Lia Gore is the Chief of Pediatric Oncology, Hematology and Bone Marrow Transplant at Children’s Hospital Colorado. She says Vincristine is the backbone of many chemotherapy regimens used. “It is actually a critical element of therapy for leukemia, for some childhood brain tumors, for several other kinds of cancers,” Dr. Gore said. She says there are two primary companies that produce Vincristine, and one recently decided to stop supplying the drug. Dr. Gore says hospitals were given very little warning. “Teva [Pharmaceutical Industries Ltd.] which was a very large supplier – large volume supplier – just decided to stop making this drug. They cited a ‘business decision.’” Dr. Gore says a drug as common and basic as Vincristine isn’t as profitable. The other company, Pfizer, has stated it'’s planning to 2265

来源：资阳报